Pooled analyses that combined samples from two separate pharmacogenetic trials found that the AGES formula had both a main effect and a moderating effect in altering the efficacy of bupropion (vs. placebo) on time to first lapse. The main effect finding suggests that AGES captures genetic variation that might alter several endophenotypes underpinned by dopaminergic circuitry that promote lapse behavior. Candidate endophenotypes include inhibitory control (54), attentional bias toward smoking stimuli (54), urge to smoke (55), anhedonia (54), diminished positive affect (55), and negative affect (55).
